← Eichor
Study identifier: NCT06194591 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Nephrospec Switzerland

Condition: Chronic Kidney Diseases · Hypertension  ·  Sponsor: Menno Pruijm

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to 82 Years
Healthy volunteersNo

About this study

This is a randomized, double-blind sham-controlled monocentric trial. 30 patients that are diagnosed with hypertension and with moderate to severe chronic kidney disease are included in this trial. 20 of them are randomized into the active treatment arm, 10 into the sham arm. Low-intensity extracorporal shock wave (Li-ESWT) sessions (arm1) or sham sessions (arm2), will be administered with a dedicated probe within three consecutive weeks to the kidneys of patients.The study will add data to the effects of the shock wave treatment on blood pressure and will assess whether this treatment improves renal function, perfusion and oxygenation. The study includes a third arm (arm3) in which treatment sessions are administered to patients that were in the placebo group in the first phase of the study (arm2).

This description comes directly from the study's public registry record.

Talk to the study team

Menno Pruijm, Dr  ·  +41 (0)21 314 13 58  ·  menno.pruijm@chuv.ch

Wendy Brito  ·  Wendy.Brito@chuv.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Nephrology, Centre Hospitalier Universitaire VaudoisLausanne, Canton of Vaud, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06194591